WO2012095509A1 - Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool - Google Patents

Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool Download PDF

Info

Publication number
WO2012095509A1
WO2012095509A1 PCT/EP2012/050478 EP2012050478W WO2012095509A1 WO 2012095509 A1 WO2012095509 A1 WO 2012095509A1 EP 2012050478 W EP2012050478 W EP 2012050478W WO 2012095509 A1 WO2012095509 A1 WO 2012095509A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid composition
composition according
body weight
fraction
cancer
Prior art date
Application number
PCT/EP2012/050478
Other languages
English (en)
Other versions
WO2012095509A8 (fr
Inventor
Markus Graf Matuschka Von Greiffenclau
Haruhiko Inufusa
Original Assignee
Tima Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tima Foundation filed Critical Tima Foundation
Publication of WO2012095509A1 publication Critical patent/WO2012095509A1/fr
Publication of WO2012095509A8 publication Critical patent/WO2012095509A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention refers to a liquid composition
  • a liquid composition comprising Vitamin C, L-glutamine and/or L-glutamic acid, L-cysteine and/or L-cystine, riboflavin, succinic acid, fumaric acid, coenzyme Q 10, niacin and hydrogen carbonate, phosphate or any other buffering system, in particular for use as a food composition, dietary or food supplementation, and pharmaceutical composition, respectively.
  • the present invention refers further to the composition according to the invention for use in the treatment and/or prophylaxis of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, tumour metastasis and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer
  • the present invention particularly addresses the problem of accumulation of acetaldehyde after rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non- Caucasian type genetic structure. It is assumed that drinking alcoholic beverages is associated with an increased risk for neuropathy diseases. Ethanol induces a lot of effects on the brain and nerve system which leads to change in behaviour, motor coordination and, in the extreme case, brain damage. In particular, peripheral nerve polyneuropathy is commonly observed in alcoholic patients.
  • One possible mediator of the alcohol effects is acetaldehyde, a highly toxic metabolite of ethanol.
  • Acetaldehyde is a highly reactive molecule with oxidative activity and has cytotoxic effects and modifies proteins in the cells, leading to their dysfunction.
  • estrogen levels in female drinkers appear to be an important mechanism for development of breast cancer.
  • One possible mechanism for the increase of estrogen is that overproduced acetic acid after drinking is converted to steroids.
  • the possible role of acetaldehyde for the alcohol-induced breast cancer appears to be evident.
  • Ethanol taken into the body is eliminated by its oxidation, mainly in the liver.
  • Ethanol (CH 3 CH 2 OH) is first metabolised to acetaldehyde (CH 3 CHO) by alcohol dehydrogenase (ADH), and then acetaldehyde (CH 3 CHO) is further metabolised to acetic acid (CH 3 COOH) by aldehyde dehydrogenase (ALDH), mainly by liver aldehyde dehydrogenase 2 (ALDH2).
  • ALDH2 Most of acetaldehyde generated during alcohol metabolism is promptly eliminated by ALDH2, the low Km ALDH.
  • ALDH2*2 has a single point mutation (G— >A) in exon 12 of the active ALDH2*1 gene. This mutation results in a substitution of glutamic acid (Glu) at amino acid position 487 by lysine (Lys).
  • Glu glutamic acid
  • Lys lysine
  • the average peaks of blood acetaldehyde concentrations of ALDH2* 1/2*2 heterozygotes and ALDH2*2/2*2 homozygotes after drinking of a small amount of ethanol (0.1 g/kg body weight) are five times and 18 times, respectively, of that found in ALDH2* 1/2*1 homozygotes after drinking of moderate amount of ethanol (0.8 g/kg body weight).
  • the amount of acetaldehyde in saliva is increased in ALDH2* 1/2*2 heterozygotes given alcohol, and its level falls when alcohol oxidation of active ALDH2* 1/2*1 homozygotes is inhibited by an ALDH inhibitor 4-methylpyrazol.
  • acetaldehyde oxidation is strikingly impaired in individuals with ALDH2*2 allele. Deficiency of ALDH2 activity is associated with an increased risk of cancer and therefore acetaldehyde is regarded as a carcinogen. In fact, acetaldehyde can damage culture hepatocytes and results in secondary hyper proliferation.
  • ALDH2 deficiency is associated with an increased risk of polyneuropathy and of late-onset Alzheimer' s disease.
  • sensory conduction time is significantly longer in Japanese alcoholic patients with hypoactive ALDH2*2 allele than that in active ALDH2* 1/2*1 homozygotes, indicating dysfunction of peripheral neurons of the formers.
  • the experimental neuronal cell system in which ALDH is genetically inactivated, becomes highly vulnerable to exogenously added aldehyde metabolite, indicating that oxidative stress caused by acetaldehyde considerably damage neuronal cells.
  • ALDH2 deficiency is associated with an increase of the risk of breast cancer.
  • Acetaldehyde has a lipophilic nature and accumulates in adipose tissues. Mammary gland is enriched in fat and other lipophilic tissues. It is concluded that drinking alcoholic beverages is associated with increases risk for breast cancer. The possible role of acetaldehyde for the alcohol-induced breast cancer is thus assumed as well.
  • HV Hepatitis viruses
  • HVB Hepatitis viruses
  • HVC Hepatitis viruses
  • epidemiological surveys are considered to support that ALDH2 deficiency is also associated with an increased risk of liver cancer for alcohol drinkers with or without hepatitis viruses. This supports the notion that acetaldehyde is closely involved in the carcinogenesis of hepatocytes in human alcohol drinkers.
  • alcoholic beverages are carcinogenic to humans and causally related to cancer of the oral cavity, pharynx, larynx and esophagus.
  • ALDH2 deficiency is also associated with an increased risk of cancer of the oral cavity, pharynx, larynx and esophagus.
  • Epithelial cells in these upper digestive tract are attacked by acetaldehyde not only diffused from blood but also secreted from salivary glands after drinking, especially in persons with ALDH2*2 allele.
  • the supplement mix according to the invention accelerates the disappearance of alcohol and acetaldehyde after drinking in not only ALDH2* 1/2*1 homozygotes but ALDH2* 1/2*2 heterozygotes.
  • the supplement according to the invention effectively accelerates alcohol metabolism, and is expected to suppress the secretion of acetaldehyde from salivary glands. Therefore, the supplement according to the invention can be used to diminish the risk of cancer of the oral cavity, pharynx, larynx and esophagus.
  • alcoholic pancreatitis is the most common type (68.5%) of chronic pancreatitis in males.
  • Chronic pancreatitis has been indicated as a risk factor for pancreatic cancer. While smoking is a well- documented risk factor for the development of pancreatic cancer, it appears that ALDH2 deficiency increases the risk of pancreatic cancer in smokers and it is assumed that alcohol increases the risk of pancreatic cancer of smokers. These data collectively suggest that alcohol, most possibly its metabolite acetaldehyde, takes part in the carcinogenesis of pancreatic cells. It appears that ALDH2 deficiency is also associated with an increase of the risk of pancreatic cancer.
  • compositions in solid dosage form are available. Since the amount of composition to be administrated to a subject having a desired effect, may be relative high, e.g. about 3 g, the composition has to be administrated in form of large capsules or tablets or a plurality of tables have to be taken.
  • compositions effective in reducing alcohol induced diseases in an appropriate dosage form.
  • neuropathy refers to any disease or abnormality of the neurons of the nervous system.
  • neuroopathy means a disorder of the peripheral nervous system, affecting nerves anywhere except brain and the spinal cord.
  • a non-limiting example for neuropathy is alcoholic polyneuropahy which is characterized by numbness, abnormal sensations called dysesthesias and allodynias that occur either spontaneously or in reaction to external stimuli, and a characteristic form of pain, called neuropathic pain or neuralgia.
  • neurodegenerative disease refers to any disease or abnormality of the nervous system caused by deterioration of neurons, which include death of neurons and functional loss of neurotransmitters.
  • Non-limiting examples for a neurodegernative disease are Alzheimer's disease and Parkinson's disease.
  • composition refers to any kind of composition which is eatable and/or drinkable without causing toxic symptoms in the subject eating or drinking the respective composition.
  • supply refers to a composition which is consumed in addition to the daily meals or in between.
  • dietary supplement refers to a composition which is consumed in addition to the daily meals or in between.
  • food supplement refers to a composition which is consumed in addition to the daily meals or in between.
  • late-onset Alzheimer's disease refers to the onset of Alzheimer's disease in elderly people, in particular in people being 65 years old and older.
  • flushing syndrome refers to the flushing as a consequence of drinking alcohol. Flushing is associated with the erythema (reddening caused by dilation of capillaries) of the face, neck, and shoulder, after consumption of alcohol. Flushing after alcohol consumption is often associated with a range of symptoms: dizziness, nausea, headaches, an increased pulse, occasional extreme drowsiness, and occasional skin swelling and itchiness. There symptoms are collectively called “Flushing syndrome” or "Asian flush”.
  • oropharyngolaryngeal cancer refers to cancers derived from oral cavity, pharynx, larynx or upper esophagus. At early stage of the cancer of this area, the origin could be determined. However, very often, the cancer of this area is found at the late invasive stage and the origin cannot be determined. Therefore, cancers arising from these sources are collectively termed “oropharyngolaryngeal cancer”.
  • liquid composition refers to an amount of medication to be taken at one time, optionally in regular intervals. According to the present invention the object is attained by a liquid composition comprising the following substances:
  • Vitamin C L-glutamine and/or L-glutamic acid, L-cysteine and/or L-cystine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, niacin and optionally dextrose.
  • the single substances of the composition according to the present invention are solved in a liquid, in particular in water.
  • hydrogen carbonate also called bicarbonate
  • phosphate or any other buffering system prevents the acidic effect of fumaric acid and succinic acid by neutralizing.
  • the composition according to the present invention comprises hydrogen carbonate, phosphate or any other buffering system in a final concentration ranging from and including 0.0036 M to 4.55 M, 0.0091 M to 1.82 M, 0.0136 M to 0.45M or 0.036 M to 0.073 M.
  • the composition according to the present invention comprises hydrogen carbonate, phosphate or any other buffering system in a final concentration of about 0.0036 M, 0.0055 M, 0.0073 M, 0.0091 M, 0.0136 M, 0.019 M, 0.0227 M, 0.027 M, 0.0318 M, 0.036 M, 0.055 M, 0.073 M, 0.091 M, 0.136 M, 0.18 M, 0.45 M, 0.91 M, 1.82 M or 4.55 M.
  • riboflavin fraction of the composition of the present invention riboflavin phosphate sodium salt or water soluble compounds containing riboflavin is used.
  • composition according to the present invention comprising coenzyme Q10, riboflavin, L-cystine, niacin, Vitamin C, succinic acid, fumaric acid, L- glutamine and optionally dextrose.
  • composition according to the present invention stimulates the activity or enhances the production of a particular alcohol dehydrogenase enzyme, namely the ADH, so that the production of acetaldehyde and the ethanol metabolism process is accelerated and the alcohol induced peak load on the human organism is reduced. Furthermore, the enzymatic activity of the aldehyde dehydrogenase ALDH2 is enhanced, so that the metabolisation of acetaldehyde is supported.
  • a particular alcohol dehydrogenase enzyme namely the ADH
  • composition of matter according to the present invention accelerates the disappearance of alcohol and acetaldehyde after drinking.
  • the composition is active preferably in ALDH2* 1/2*1 homozygote and ALDH2* 1/2*2 heterozygote subjects.
  • the composition according to the present invention effectively accelerates alcohol metabolism and suppresses the secretion of acetaldehyde from salivary glands. Therefore, the composition according to the present invention can be used to diminish the risk of neuropathy, neurodegenerative diseases, e.g. late-onset Alzheimer's disease, and of cancer, in particular of pancreatic, esophageal, oropharyngolarynal, colorectal, lung, liver and breast cancer.
  • the composition according to the present invention lowers the risk of several forms of cancer such as pancreatic, esophageal, oropharyngolarynal, colorectal, lung, liver and/or breast cancer.
  • composition according to the present invention decreases the risk of pancreatic cancer, preferably for alcohol drinkers with smoking habit, especially those who have the ALDH2*2 allele.
  • composition according to the invention reduces the risk of breast and liver cancer, preferably for alcohol drinkers, especially those who have the ALDH2*2 allele.
  • the composition according to the present invention contains several substances, which are often deficient in patients with alcoholic neuropathy.
  • the composition is thus effective in reducing a flushing syndrome, reducing an alcoholic intoxication, reducing the likelihood of headaches and also helps to avoid or ease an alcohol induced hangover the day after.
  • the niacin-fraction (Vitamin B3) included in the composition functions as nicotinamide adenine dinucleotide (NAD), which is effective towards a coenzyme to alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Said niacin-fraction is provided to accelerate ethanol metabolism.
  • this composition should be taken prior to consumption of alcohol, e.g. about 15 to 5 minutes and in case of high alcohol consumption again whilst consuming alcohol.
  • the mass of the composition taken by the consumer should be in the range of about 70 to 120 % of the mass of the alcohol included in the consumed drinks.
  • a standard dose might include about 1.0 g Vitamin C, 1.0 g L-glutamine and/or L-glutamic acid, 500 mg L-cysteine and/or L-cystine, 40 mg riboflavin, 100 mg succinic acid or one of its salts (e.g. succinate), 100 mg fumaric acid or one of its salts (e.g.
  • the relation of the components of the composition is oriented towards the above given relation.
  • the overall dosage may be adapted to the body mass weight of the consumer.
  • the standard dose of the composition of the present invention includes 100 mg coenzyme Q10, 40 mg riboflavin, 500 mg L-cystine, 10 mg niacin, 1000 mg Vitamin C, 100 mg succinic acid, 100 mg fumaric acid and 1000 mg L-glutamine solved in 40 ml water and 4 ml of 0.04, 0.06, 0.08, 0.1, 0,15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.6, 0.8, 1, 1.5, 2, 5, 10, 20 and/or 50 M hydrogen carbonate, phosphate or any other buffering system is added.
  • the standard dose of the composition of the present invention includes 100 mg coenzyme Q10, 40 mg riboflavin, 500 mg L-cystine, 10 mg niacin, 1000 mg Vitamin C, 100 mg succinic acid, 100 mg fumaric acid and 1000 mg L- glutamine solved in 40 ml water and 4 ml of 0.4 M sodium hydrogen carbonate is added.
  • composition according to the present invention is intended to prevent too much acetaldehyde passing into the mitochondrial matrix and to suppress self blockade of the enzymatic activity of ALDH and thus facilitate the decomposition of acetaldehyde.
  • composition according to the present invention facilitates in a synergetic manner an early decrease of the level of acetaldehyde after drinking and simultaneously provides a protective effect in respect of the suppression of the generation of free radicals.
  • the composition is to be administered as a food composition or food or dietary supplement it is preferably in such a form, preferably as ingredients of a kind of aperitif, that it allows the food composition or food or dietary supplement to be consumed within a restaurant or a bar prior to consuming alcoholic drinks.
  • the food composition, food or dietary supplement is preferably constituted in a manner wherein a dosage of same is in a liquid form.
  • the composition according to the present invention is provided as a solution, emulsion or suspension.
  • the compounds of the composition according to the present invention are solubilized or microparticulate active agents.
  • the volume of the composition according to the present invention taken by the consumer can be determined with respect to the volume of alcohol which is expected to be consumed.
  • the composition according to the present invention may also be in the form of a liquid, in particular a syrup-type liquid or a drink. It is possible to provide the composition in the appearance of a soft drink in a small bottle.
  • the food composition, food or dietary supplement taken orally may supplement the diet.
  • the food composition, food or dietary supplement may also be provided in bars, drinks, shakes and other food products.
  • a food composition, food or dietary supplement is not intended to be the sole item of a meal or diet.
  • the food composition, food or dietary supplement may be taken before, after or simultaneously with a meal.
  • the food composition, food or dietary supplement may be taken once or several times a day.
  • the food composition, food or dietary supplement may be taken at any time of day.
  • the composition according to the present invention comprises a niacin fraction in a quantity ranging from and including 0.01 to 2 mg/kg body weight, 0.1 to 1.5 mg/kg body weight or 0.2 to 0.75 mg/kg body weight, preferably 0.125 mg/kg body weight.
  • the composition according to the present invention comprises a L-cystine or L- cysteine fraction in a quantity ranging from and including 1 to 15 mg/kg body weight, 2.5 to 10 mg/kg body weight or 5 to 8 mg/kg body weight, preferably 6.25 mg/kg body weight.
  • the composition according to the present invention comprises a L-glutamine and/or L-glutamic acid fraction in a quantity ranging from and including 1 to 20 mg/kg body weight, 5 to 15 mg/kg body weight or 7 to 13 mg/kg body weight, preferably 12.5 mg/kg body weight.
  • the composition according to the present invention comprises a riboflavin fraction in a quantity ranging from and including 0.05 to 2 mg/kg body weight, 0.1 to 1.5 mg/kg body weight or 0.2 to 0.75 mg/kg body weight, preferably 0.5 mg/kg body weight.
  • the composition according to the present invention comprises a succinic acid fraction in a quantity ranging from and including 0.1 to 10 mg/kg body weight, 0.5 to 5 mg/kg body weight or 0.75 to 2 mg/kg body weight, preferably 1.25 mg/kg body weight.
  • the composition according to the present invention comprises a fumaric acid fraction in a quantity ranging from and including 0.1 to 10 mg/kg body weight, 0.5 to 5 mg/kg body weight or 0.75 to 2 mg/kg body weight, preferably 1.25 mg/kg body weight.
  • the composition according to the present invention comprises a coenzyme Q10 fraction in a quantity ranging from and including 0.1 to 10 mg/kg body weight, 0.5 to 5 mg/kg body weight or 0.75 to 2 mg/kg body weight, preferably 1.25 mg/kg body weight.
  • the composition according to the present invention comprises a Vitamin C fraction in a quantity ranging from and including 1 to 20 mg/kg body weight, 5 to 15 mg/kg body weight or 7 to 13 mg/kg body weight, preferably 12.5 mg/kg body weight.
  • the composition is constituted in a manner wherein a dosage of same, comprises a dextrose fraction ranging from and including 10 to 200 mg/kg body weight, 50 to 150 mg/kg body weight or 70 to 130 mg/kg body weight, preferably 125 mg/kg body weight.
  • a dosage for a person with a body weight of about 80 kg includes a dextrose fraction of approx. 75%. Such a dosage is to provide a considerable moderation in degrading about 18 ml alcohol.
  • the composition is constituted in a manner wherein a dosage of same includes a Vitamin C fraction of about 35 mass% i.e. a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.0 g, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • a dosage of same includes a Vitamin C fraction of about 35 mass% i.e. a quantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.0 g, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a L-glutamine and/or L-glutamic acid fraction of about 35 mass%, i.e. a quantity of said L- glutamine and/or L-glutamic acid fraction in the range from 0.78 to 1.18 g, preferably 1.0 g, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • a dosage of same includes a L-glutamine and/or L-glutamic acid fraction of about 35 mass%, i.e. a quantity of said L- glutamine and/or L-glutamic acid fraction in the range from 0.78 to 1.18 g, preferably 1.0 g, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a L-cystine or L-cysteine fraction of about 17.6 mass%, i.e. a quantity of said L-cystine or L- cysteine fraction in the range from 460 to 540 mg, preferably 500 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • a dosage of same includes a L-cystine or L-cysteine fraction of about 17.6 mass%, i.e. a quantity of said L-cystine or L- cysteine fraction in the range from 460 to 540 mg, preferably 500 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a riboflavin fraction, preferably riboflavin sodium phosphate or water soluble compounds containing riboflavin of about 1.41 mass% i.e. a quantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a succinic acid fraction or one of its salts (e.g. succinate) of about 3.5 mass%, i.e.
  • the composition is constituted in a manner wherein a dosage of same includes a fumaric acid fraction or one of its salts (e.g. fumarate) of about 3.5 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably 100 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • a dosage of same includes a fumaric acid fraction or one of its salts (e.g. fumarate) of about 3.5 mass%, i.e. a quantity of said fumaric acid in the range from 90 to 110 mg, preferably 100 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a coenzyme Q10 fraction of about 3.5 mass%, i.e. a quantity of said coenzyme fraction in the range from 30 to 200 mg, preferably 100 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same includes a niacin fraction of about 0.35 mass%, i.e. a quantity of said coenzyme fraction in the range from 1 to 20 mg, preferably 10 mg, within a dose of 2.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the composition is constituted in a manner wherein a dosage of same, includes a dextrose fraction of about 77.82 mass%, i.e. a quantity of dextrose in the range from 7.2 to 12.8 g, preferably 10.0 g within a dose of 12.85 g in 44 ml for a person with a body weight of about 80 kg.
  • the standard dose of the composition according to the invention comprises a sodium hydrogen carbonate fraction ranging from and including 0.1 to 50 mg/kg body weight, 0.5 to 25 mg/kg body weight, 1.5 to 20 mg/kg or 1 to 8 mg/kg body weight, preferably 1.68 mg/kg body weight.
  • composition according to the invention is constituted in a manner wherein a dosage of same includes a sodium hydrogen carbonate fraction of about 4.5 mass%, i.e. a quantity of said sodium hydrogen carbonate fraction in the range from 1 to 200 mg, preferably 134.4 mg, within a dose of 2.9844 g for a person with a body weight of about 80 kg. More preferably each ingredient of the composition is in the range from about 0.01 to about 100 gram, preferably from about 0.05 to 50 gram.
  • composition is considered to provide the following achievements: 1. Acceleration of ethanol metabolism by enhancing the process of ethanol oxidation into acetaldehyde.
  • the first and second achievements are believed to be performed by a) Accelerating ADH and ALDH reactions by constantly providing coenzyme NAD b) Accelerating the reoxidation from NADH+H + to NAD in the electron transport system c) Accelerating the transportation of NAD through mitochondrial membrane
  • NAD nicotinamide adenine dinucleotide
  • active form of niacin functions as a coenzyme in both ADH (catalyzing the reaction of ethanol to acetaldehyde) and ALDH (catalyzing the reaction of acetaldehyde to acetic acid) reactions.
  • ADH catalyzing the reaction of ethanol to acetaldehyde
  • ALDH catalyzing the reaction of acetaldehyde to acetic acid
  • NADH cannot penetrate the mitochondrial membrane. Therefore, NADH has to be reoxidized to NAD via malate/aspartate shuttle. Oxaloacetate can be reduced to malate with the aid of NADH. Malate can penetrate the mitochondrial membrane and then oxidized to oxaloacetate to form NADH in the mitochondria. NADH is then oxidized to NAD in the electron transport system. In order to maintain oxaloacetate -> malate reaction in the cytosol, oxaloacetate should move to the cytosol.
  • composition according to the present invention contains glutamine which is easily converted to glutamic acid as well as fumaric acid and succinic acid.
  • glutamine which is easily converted to glutamic acid as well as fumaric acid and succinic acid.
  • the latter two materials are easily metabolized to malate in the Krebs cycle.
  • Our invention effectively supports the operation of malate/asparate shuttle to regulate NAD for ADH.
  • Riboflavin will quickly be transformed to FMN, which together with coenzyme Qio is the determining substance for the speed of the reoxidation of NADH+H + to NAD + in the mitochondrial electron transport system.
  • FMN and coenzyme Qio are available, the more this process is speeded up and, because more NAD is available, the metabolism of acetaldehyde as well as ethanol is accelerated.
  • the third achievement, the activation of the Krebs (citrate) cycle is achieved by the inclusion of succinic acid and fumaric acid. Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria. They are easily converted to oxaloacetic acid, which reacts with acetyl-CoA (metabolically active form of acetic acid) for metabolism to carbon dioxide and water. Therefore, these compounds stimulate the elimination of acetic acid.
  • succinic acid and fumaric acid Both substances activate the second half of the citrate cycle and thereby activate the aerobic oxidation process in mitochondria. They are easily converted to oxaloacetic acid, which reacts with acetyl-CoA (metabolically active form of acetic acid) for metabolism to carbon dioxide and water. Therefore, these compounds stimulate the elimination of acetic acid.
  • the fourth achievement, the elevation of anti-oxidant levels, is achieved by the inclusion of L-cysteine, ascorbic acid (vitamin C) and also of L-glutamine and/or L-glutamic acid.
  • Cysteine should provide a strong anti-oxidant effect as well as ascorbic acid.
  • the human body transforms cysteine and glutamine to glutathione ( ⁇ -glutamyl-cysteinyl-glycine), which specially protects against the toxic effects of acetaldehyde. To reach an optimal level of gluthatione, it is important to combine cysteine with glutamine and give twice as much ascorbic acid as cysteine.
  • the present invention relates to a composition for reducing alcohol induced risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease and of cancer, in particular of esophageal, oropharyngolarynal, colorectal, lung, liver, breast and/or pancreatic cancer by accelerating an alcohol degradation process in respect to ethanol metabolism within the human body.
  • the composition of the present invention includes the following substances in physiologically relevant amount: Vitamin C, L-glutamine and/or L- glutamic acid, L-cysteine and/or L-cystine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, niacin and optionally dextrose.
  • Another aspect of the invention refers to the use of the composition according to the present invention for reducing alcohol induced risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease and of cancer, in particular of esophageal, oropharyngolarynal, colorectal, lung, liver, breast and/or pancreatic cancer.
  • Another aspect of the invention refers to the use of the composition according to the present invention for accelerating the alcohol degradation process within the human body.
  • composition according to the present invention can be used as a food composition, food or dietary supplement.
  • compositions according to the present invention can be used as a pharmaceutical.
  • the pharmaceutical or medicament, respectively, can be used for example for the manufacture of a medicament for the treatment and/or prophylaxis of cancer.
  • cancers can be selected from breast cancer, liver cancer, pancreatic cancer, esophageal cancer, colorectal cancer, lung cancer and oropharyngolaryngeal cancer.
  • composition of the present invention can also be used for the manufacture of a medicament for the treatment and/or prevention of tumour metastasis in general.
  • composition of the present invention can also be used for the manufacture of a medicament for the treatment and/or prophylaxis of neuropathy and treatment and/or prophylaxis of a neurodegenerative disease, in particular of late-onset Alzheimer' s disease.
  • composition according to the present invention can also be used for the manufacture of a medicament for the treatment and/or prophylaxis of hangover, flushing syndrome, headache and/or alcoholic intoxication.
  • composition according to the present invention is present in the form of a liquid.
  • composition according to the present invention is in the form of a small drink unit.
  • composition according to the present invention is in the form of a syrup.
  • the composition according to the present invention is a liquid, more preferably the liquid is water.
  • the single substances of the composition according to the present invention are solved in a liquid, in particular in water.
  • the present invention relates to a food composition, food or dietary supplementation, and pharmaceutical composition according to the present invention for reducing alcohol induced risk of neuropathy and/or neurodegenerative diseases including late-onset Alzheimer's disease, esophageal cancer, oropharyngolarynal cancer, breast cancer, liver cancer, lung cancer, colorectal cancer and/or pancreatic cancer, said composition including niacin for affecting an alcohol degrading process in particular in respect to ethanol metabolism within the human body, and substances, in particular substances mentioned above, providing the following effects within the human body:
  • the present invention relates to a composition
  • a composition comprising Vitamin C, L-glutamine and/or L-glutamic acid, L-cysteine and/or L-cystine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, niacin and optionally dextrose.
  • Vitamin C Vitamin C
  • L-glutamine and/or L-glutamic acid L-cysteine and/or L-cystine
  • riboflavin riboflavin
  • succinic acid fumaric acid
  • coenzyme Q10 coenzyme Q10
  • niacin optionally dextrose
  • the present invention relates to a method of treating a disorder, disease or condition in a subject in need of treatment and/or prevention, which method comprises administering to said subject an effective amount of composition according to the present invention.
  • said method of treatment may be for the treatment and/or prevention of neuropathy, of a neurodegenerative disease, in particular of late-onset Alzheimer's disease, of hangover, flushing syndrome, headache, alcoholic intoxication, tumour metastasis and/or cancer, in particular of breast cancer, liver cancer, colorectal cancer, lung cancer, pancreatic cancer, esophageal cancer and oropharyngolaryngeal cancer.
  • the supplement consists of the following ingredients:
  • Coenzyme Q10 Ingredients of the supplement except Coenzyme Q10 were purchased from Sigma Aldrich Japan (Tokyo, Japan). *CoQ10P40 (Nisshin Pharma, Tokyo Japan) was used as Coenzyme Q 10. CoQ10P40 contains 40 % weight of Coenzyme Q10 and easy soluble to water.
  • Example 2 Alcohol and volunteers Three healthy adult volunteers were agreed with alcohol consumption and blood sampling. Four hundred ml of red wine which contains 12.5% of ethanol was used as alcohol, and this amount is exactly same as 50 gram of ethanol. The supplement was administered orally to test subjects 20 min prior to alcohol ingestion.
  • Example 3 Blood sampling, and the measurement of blood ethanol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une composition liquide comprenant de la vitamine C, de la L-glutamine et/ou de l'acide L-glutamique, de la L-cystéine et/ou de la L-cystine, de la riboflavine, de l'acide succinique, de l'acide fumarique, une coenzyme Q 10, de la niacine et du carbonate, phosphate d'hydrogène ou tout autre système de tamponnage, ladite composition étant, en particulier, destinée à être utilisée à titre de composition alimentaire, de supplément diététique ou alimentaire, et de composition pharmaceutique, respectivement. Cette invention concerne, en outre, la composition selon l'invention destinée à être utilisée pour traiter et/ou prévenir la neuropathie, les maladies neurodégénératives comprenant la maladie d'Alzheimer à début tardif, la métastase tumorale et le cancer, en particulier, le cancer du pancréas, de l'œsophage, oropharyngolaryngé, hépatique, colorectal, du poumon et/ou du sein.
PCT/EP2012/050478 2011-01-14 2012-01-13 Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool WO2012095509A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151001 2011-01-14
EP11151001.2 2011-01-14

Publications (2)

Publication Number Publication Date
WO2012095509A1 true WO2012095509A1 (fr) 2012-07-19
WO2012095509A8 WO2012095509A8 (fr) 2012-10-04

Family

ID=45509476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/050478 WO2012095509A1 (fr) 2011-01-14 2012-01-13 Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool

Country Status (1)

Country Link
WO (1) WO2012095509A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072441A1 (fr) * 2011-11-15 2013-05-23 Tima Foundation Composition pour la protection contre des effets qui endommagent les cellules
WO2020251994A1 (fr) * 2019-06-12 2020-12-17 American Bluetec Company Compositions de complément alimentaire pour le traitement de troubles neurologiques, et procédés de traitement de troubles neurologiques les utilisant
CN114891808A (zh) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
WO2007016954A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de cancer du sein induit par l’alcool ou les médicaments
WO2007016953A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de cancer du foie induit par l’alcool
WO2007017139A1 (fr) * 2005-07-29 2007-02-15 Tima Foundation Composition destinée à modérer le métabolisme de l’alcool et à réduire le risque de maladies induites par l’alcool
WO2007016950A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de maladie neurodégénérative induite par l’alcool
WO2007016949A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de neuropathie induite par l’alcool
WO2008071790A2 (fr) * 2006-12-15 2008-06-19 Tima Foundation Nouvelles compositions et leurs utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006910A1 (en) * 2000-05-18 2002-01-17 Dmitri Miasnikov Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
WO2007016954A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de cancer du sein induit par l’alcool ou les médicaments
WO2007016953A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de cancer du foie induit par l’alcool
WO2007017139A1 (fr) * 2005-07-29 2007-02-15 Tima Foundation Composition destinée à modérer le métabolisme de l’alcool et à réduire le risque de maladies induites par l’alcool
WO2007016950A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de maladie neurodégénérative induite par l’alcool
WO2007016949A1 (fr) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition réduisant les risques de neuropathie induite par l’alcool
WO2008071790A2 (fr) * 2006-12-15 2008-06-19 Tima Foundation Nouvelles compositions et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANCET ONCOL, vol. 7, 2006, pages 149 - 156

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072441A1 (fr) * 2011-11-15 2013-05-23 Tima Foundation Composition pour la protection contre des effets qui endommagent les cellules
JP2014533295A (ja) * 2011-11-15 2014-12-11 ティーマ ファウンデーション 細胞傷害作用からの防御のための組成物
US9089548B2 (en) 2011-11-15 2015-07-28 Tima Foundation Composition for protection against cell-damaging effects
WO2020251994A1 (fr) * 2019-06-12 2020-12-17 American Bluetec Company Compositions de complément alimentaire pour le traitement de troubles neurologiques, et procédés de traitement de troubles neurologiques les utilisant
CN114891808A (zh) * 2022-06-21 2022-08-12 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物
CN114891808B (zh) * 2022-06-21 2023-10-27 珠海丽凡达生物技术有限公司 编码ALDH2多肽的mRNA分子、应用及mRNA药物

Also Published As

Publication number Publication date
WO2012095509A8 (fr) 2012-10-04

Similar Documents

Publication Publication Date Title
US9402849B2 (en) Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
Penberthy et al. Niacin
JP5019875B2 (ja) 糖新生によりアルコール代謝を促進又は疲労を改善する組成物
EP1374863B1 (fr) Compositions d'acides amines utilisees pour ameliorer le malfonctionnement hepatique
WO2007016953A1 (fr) Composition réduisant les risques de cancer du foie induit par l’alcool
EP3359138B1 (fr) Supplémentation diététique pour obtenir l'homéostasie oxy-redox et la stabilité épigénétique
WO2012095509A1 (fr) Composition visant à accélérer le métabolisme de l'alcool et à réduire le risque de maladies induites par l'alcool
US20230117757A1 (en) Coenzyme q production accelerator and method for accelerating coenzyme q production
WO2007016949A1 (fr) Composition réduisant les risques de neuropathie induite par l’alcool
JP2007246478A (ja) アセトアルデヒド代謝促進剤
WO2007016950A1 (fr) Composition réduisant les risques de maladie neurodégénérative induite par l’alcool
TW201309282A (zh) 一種用於加速酒精代謝及用於降低酒精誘導的疾病的風險的組合物
US20230270711A1 (en) Improved Anti-Hangover Composition, Its Preparation and Uses
JPS61134313A (ja) アルデヒドの毒性抑制剤
WO2007016954A1 (fr) Composition réduisant les risques de cancer du sein induit par l’alcool ou les médicaments
WO2007016952A1 (fr) Composition réduisant les risques de cancer de l’oesophage ou de l’oropharyngolaryngée induit par l’alcool
US20240058411A1 (en) Composition for treating and/or preventing a hangover
JP2004224796A (ja) アセトアルデヒド毒性の抑制剤
Nolan An analysis of the effects of various compounds on alcohol and high-fat-diet-induced steatosis in rats and mice
WO2007016951A1 (fr) Composition réduisant les risques de cancer du pancréas induit par l’alcool

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12700654

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12700654

Country of ref document: EP

Kind code of ref document: A1